FDA Accepts Eisai’s Lecanemab Application for Early July Target

Eisai said on March 6 that the US FDA has accepted its application seeking full traditional approval for its Alzheimer’s treatment lecanemab. The drug was designated for priority review, with the agency setting its target action date for July 6...read more